BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 29180476)

  • 1. A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance.
    Arnst KE; Wang Y; Hwang DJ; Xue Y; Costello T; Hamilton D; Chen Q; Yang J; Park F; Dalton JT; Miller DD; Li W
    Cancer Res; 2018 Jan; 78(1):265-277. PubMed ID: 29180476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.
    Arnst KE; Wang Y; Lei ZN; Hwang DJ; Kumar G; Ma D; Parke DN; Chen Q; Yang J; White SW; Seagroves TN; Chen ZS; Miller DD; Li W
    Mol Pharmacol; 2019 Jul; 96(1):73-89. PubMed ID: 31043459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
    Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
    Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1
    Wang Q; Arnst KE; Wang Y; Kumar G; Ma D; White SW; Miller DD; Li W; Li W
    J Med Chem; 2019 Jul; 62(14):6734-6750. PubMed ID: 31251599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis.
    Wang Z; Chen J; Wang J; Ahn S; Li CM; Lu Y; Loveless VS; Dalton JT; Miller DD; Li W
    Pharm Res; 2012 Nov; 29(11):3040-52. PubMed ID: 22410804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
    Du T; Lin S; Ji M; Xue N; Liu Y; Zhang Z; Zhang K; Zhang J; Zhang Y; Wang Q; Sheng L; Li Y; Lu D; Chen X; Xu H
    Cancer Lett; 2020 Dec; 495():22-32. PubMed ID: 32931884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer.
    Mahmud F; Deng S; Chen H; Miller DD; Li W
    Cancer Lett; 2020 Dec; 495():76-88. PubMed ID: 32920198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
    Ahn S; Hwang DJ; Barrett CM; Yang J; Duke CB; Miller DD; Dalton JT
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):293-304. PubMed ID: 20383708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 7-Aroyl-aminoindoline-1-sulfonamides as a novel class of potent antitubulin agents.
    Chang JY; Hsieh HP; Chang CY; Hsu KS; Chiang YF; Chen CM; Kuo CC; Liou JP
    J Med Chem; 2006 Nov; 49(23):6656-9. PubMed ID: 17154496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
    Taraboletti G; Micheletti G; Rieppi M; Poli M; Turatto M; Rossi C; Borsotti P; Roccabianca P; Scanziani E; Nicoletti MI; Bombardelli E; Morazzoni P; Riva A; Giavazzi R
    Clin Cancer Res; 2002 Apr; 8(4):1182-8. PubMed ID: 11948131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.
    Li CM; Lu Y; Chen J; Costello TA; Narayanan R; Dalton MN; Snyder LM; Ahn S; Li W; Miller DD; Dalton JT
    Pharm Res; 2012 Nov; 29(11):3053-63. PubMed ID: 22760659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe.
    Bai Z; Gao M; Zhang H; Guan Q; Xu J; Li Y; Qi H; Li Z; Zuo D; Zhang W; Wu Y
    Cancer Lett; 2017 Aug; 402():81-92. PubMed ID: 28576750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic delivery of nanoparticle formulation of novel tubulin inhibitor for treating metastatic melanoma.
    Mundra V; Peng Y; Kumar V; Li W; Miller DD; Mahato RI
    Drug Deliv Transl Res; 2015 Jun; 5(3):199-208. PubMed ID: 25924699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors.
    Beckers T; Reissmann T; Schmidt M; Burger AM; Fiebig HH; Vanhoefer U; Pongratz H; Hufsky H; Hockemeyer J; Frieser M; Mahboobi S
    Cancer Res; 2002 Jun; 62(11):3113-9. PubMed ID: 12036922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SKLB060 Reversibly Binds to Colchicine Site of Tubulin and Possesses Efficacy in Multidrug-Resistant Cell Lines.
    Yan W; Yang T; Yang J; Wang T; Yu Y; Wang Y; Chen Q; Bai P; Li D; Ye H; Qiu Q; Zhou Y; Hu Y; Yang S; Wei Y; Li W; Chen L
    Cell Physiol Biochem; 2018; 47(2):489-504. PubMed ID: 29794416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity.
    Wang F; Yang Z; Liu Y; Ma L; Wu Y; He L; Shao M; Yu K; Wu W; Pu Y; Nie C; Chen L
    Bioorg Med Chem; 2015 Jul; 23(13):3337-50. PubMed ID: 25937236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tubulin colchicine site binding agent LL01 displays potent antitumor efficiency both in vitro and in vivo with suitable drug-like properties.
    Wu JD; Cui YJ; Zhou YG; Tang LQ; Zhang CM; Liu ZP
    Invest New Drugs; 2020 Feb; 38(1):29-38. PubMed ID: 30887253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site.
    Li W; Shuai W; Sun H; Xu F; Bi Y; Xu J; Ma C; Yao H; Zhu Z; Xu S
    Eur J Med Chem; 2019 Feb; 163():428-442. PubMed ID: 30530194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis.
    Deng S; Banerjee S; Chen H; Pochampally S; Wang Y; Yun MK; White SW; Parmar K; Meibohm B; Hartman KL; Wu Z; Miller DD; Li W
    Cancer Lett; 2023 Feb; 555():216046. PubMed ID: 36596380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function.
    Lindamulage IK; Vu HY; Karthikeyan C; Knockleby J; Lee YF; Trivedi P; Lee H
    Sci Rep; 2017 Aug; 7(1):10298. PubMed ID: 28860494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.